Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Therabel has introduced Loramyc, as a treatment of oropharyngeal candidiasis in immune compromised patients, in Germany.
Subscribe to our email newsletter
Developed by BioAlliance Pharma, Loramyc is a mucoadhesive gingival tablet containing miconazole administered once-a-day over 7 to 14 days.
Additionally, Therabel has made a fully dedicated team and has also signed a co-promotion agreement with Hikma Pharma for Loramyc business in Germany.
BioAlliance Pharma CEO Dominique Costantini said they are confident in Therabel and Hikma teams’ involvement and know-how to ensure Loramyc success in Germany.